Table 2.

Visual Acuity Data.

All eyes (49 eyes of 45 patients)	Mean logMAR VA	Mean Snellen VA	Median Snellen VA	Range
VA at most recent brolucizumab injection	0.3926	20/49	20/40	20/20-5/200
VA at AE onset	0.5258	20/67	20/50	20/25-3/200
Worst VA	0.6144	20/82	20/60	20/25-1/200
VA at most recent follow-upa	0.4457	20/56	20/40	20/20-1/200
3 eyes (6%) with ≥ 3-line VA loss at last follow-up, 1 eye (2%) with ≥ 6-line VA loss at last follow-up
Eyes with > 30 days’ follow-up since AE presentation (32 eyes of 30 patients)
VA at most recent brolucizumab injection	0.4485	20/56	20/40	20/20-5/200
VA at AE onset	0.5813	20/76	20/60	20/20-5/200
Worst VA	0.6864	20/97	20/75	20/25-5/200
VA at most recent follow-upb	0.4739	20/60	20/45	20/20-5/200
2 eyes (6%) with ≥ 3-line VA loss at last follow-up, 1 eye (3%) with ≥ 6-line VA loss at last follow-up

Abbreviations: AE, adverse event; VA, visual acuity.

^a Mean 74 days since last brolucizumab injection.

^b Mean 92 days since last brolucizumab injection.